Stifel Nicolaus downgrades Iridex (IRIX) to a Hold

Iridex (IRIXResearch Report) received a Hold rating and a $3.00 price target from Stifel Nicolaus analyst Thomas Stephan yesterday. The company’s shares closed yesterday at $2.61.

According to TipRanks, Stephan is an analyst with an average return of -9.7% and a 25.00% success rate. Stephan covers the Healthcare sector, focusing on stocks such as Iridex, Glaukos, and Sight Sciences.

The word on The Street in general, suggests a Hold analyst consensus rating for Iridex with a $3.00 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $9.46 and a one-year low of $2.45. Currently, Iridex has an average volume of 43.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

Read More on IRIX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More